Kura Oncology (KURA) Total Current Liabilities (2010 - 2026)
Kura Oncology (KURA) posted quarterly Total Current Liabilities of $101.5 million for Q1 2026, up 13.07% year-over-year from $89.8 million in Q1 2025, and down 13.23% quarter-over-quarter from $117.0 million in Q4 2025.
Kura Oncology (KURA) Total Current Liabilities (2010 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Total Current Liabilities for 17 consecutive years, with $101.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 13.07% year-over-year to $101.5 million; the TTM figure through Mar 2026 stood at $101.5 million (up 13.07% YoY), while the FY2025 annual figure was $117.0 million, up 48.61% from the prior year.
- Total Current Liabilities eased to $101.5 million in Q1 2026 per KURA's latest filing, from $117.0 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $121.3 million in Q3 2025 and bottomed at $17.7 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $53.6 million across 5 years, with a median of $33.5 million in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities dropped 29.49% — and 2025, when it jumped 220.39%.
- Kura Oncology's Total Current Liabilities stood at $24.1 million in 2022, then jumped by 46.58% to $35.3 million in 2023, then surged by 123.21% to $78.7 million in 2024, then surged by 48.61% to $117.0 million in 2025, then decreased by 13.23% to $101.5 million in 2026.
- Business Quant data shows KURA's Total Current Liabilities at $101.5 million in Q1 2026, $117.0 million in Q4 2025, and $121.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | 118.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 118.19 Mn |
| Mar 31, 2026 | 101.50 Mn |
| Dec 31, 2025 | 116.97 Mn |
| Sep 30, 2025 | 121.30 Mn |
| Jun 30, 2025 | 107.17 Mn |
| Mar 31, 2025 | 89.77 Mn |
| Dec 31, 2024 | 78.71 Mn |
| Sep 30, 2024 | 40.37 Mn |
| Jun 30, 2024 | 33.45 Mn |
| Mar 31, 2024 | 32.27 Mn |
| Dec 31, 2023 | 35.26 Mn |
| Sep 30, 2023 | 27.53 Mn |
| Jun 30, 2023 | 23.90 Mn |
| Mar 31, 2023 | 19.23 Mn |
| Dec 31, 2022 | 24.06 Mn |
| Sep 30, 2022 | 24.75 Mn |
| Jun 30, 2022 | 17.87 Mn |
| Mar 31, 2022 | 17.73 Mn |
| Dec 31, 2021 | 22.46 Mn |
| Sep 30, 2021 | 21.93 Mn |